期刊
EUROPEAN JOURNAL OF PHARMACOLOGY
卷 791, 期 -, 页码 395-404出版社
ELSEVIER
DOI: 10.1016/j.ejphar.2016.09.015
关键词
MicroRNA; Sarcoidosis; Lung cancer; Asthma; COPD; Lung disease
资金
- MRC [G1001367/1]
- Wellcome Trust [093080/Z/10/Z]
- NIHR Respiratory Disease Biomedical Research Unit at the Royal Brompton NHS Foundation Trust and Imperial College London
- Medical Research Council [G1000758, G1001367] Funding Source: researchfish
- MRC [G1001367] Funding Source: UKRI
MicroRNAs (miRNAs) are small non-coding RNAs which can act as master regulators of gene expression, modulate almost all biological process and are essential for maintaining cellular homeostasis. Dysregulation of miRNA expression has been associated with aberrant gene expression and may lead to pathological conditions. Evidence suggests that miRNA expression profiles are altered between health and disease and as such may be considered as biomarkers of disease. Evidence is increasing that miRNAs are particularly important in lung homeostasis and development and have been demonstrated to be the involved in many pulmonary diseases such as asthma, COPD, sarcoidosis, lung cancer and other smoking related diseases. Better understanding of the function of miRNA and the mechanisms underlying their action in the lung, would help to improve current diagnosis and therapeutics strategies in pulmonary diseases. Recently, some miRNA-based drugs have been introduced as possible therapeutic agents. In this review we aim to summarize the recent findings regarding the role of miRNAs in the airways and lung and emphasise their potential therapeutic roles in pulmonary diseases. (C) 2016 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据